ToolGen is a biotech company editing the genetic information in microbial, plant, animal, and human cells. ToolGen aims to translate the potential of its innovative platform technology into transformative products for biomedicine and agriculture.
ToolGen – genome engineering
ToolGen is focused on the development of genome editing technology. RNA-Guided ENdonucleases (RGENs) are programmable genome engineering tools developed from bacterial adaptive immune machinery (CRISPR/Cas9 system). RGEN consists of constant components (tracrRNA and Cas9) and a target-specific RNA (crRNA). The protein Cas9 forms a sequence-specific endonuclease when complexed with two RNAs, one of which guides target selection. Transfer of a custom-designed crRNA molecule together with tracrRNA and Cas9 will lead to an efficient and specific cleavage of target sequence in cells. Moreover, RGEN supports very robust production of gene-modified mouse and zebrafish. Indeed, Active RGEN (aRGEN), with all components of RGENs in active form, is the perfect option for researchers who are planning to make KO animal by direct cell injection (drosophila, c.elegans, zebrafish, mouse, rat, medaka, rabbit, etc…). Recombinant Cas9 proteins are ready-to-use reagents for your genome engineering experiments. Together with custom-designed guide RNA, Cas9 proteins will form ready-to-inject reagents suitable for an accelerated development of gene-modified animals via one-cell embryos injection. Cas9 variants for different molecular manipulation of DNA such as cleavage for original Cas9, Nicking for niCas9 (D10A) and simple binding for dCas9 (D10A/H840A) are available. ToolGen also offers DNA-directed RGEN (dRGEN), where all RGEN’s components are incorporated into plasmid-based expression system. dRGENs is compatible with any general DNA transfection/electroporation methods. Furthermore, ToolGen develops Hap1 cell line services. HAP1 is an adherent human cell line that is near-haploid. Using CRISPR/Cas9 system to engineer gene knockouts, the resulting cell lines are single cell clones bearing frameshift mutations and, as a consequence, they are completely knockouts.
ToolGen Inc. is a publicly traded biotechnology company based in Seoul (Korea). Management Team is composed by Jongmoon Kim (CEO), Jin-soo Kim (Co-founder) and Seokjoong Kim (Director of Research Institute).
More about ToolGen : www.toolgen.com